The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

@article{Robert2004TheRO,
  title={The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.},
  author={Nicholas J. Robert and Charles Le. Vogel and M. D. I.Craig Henderson and Joseph A Sparano and Michael S. Moore and Paula Silverman and Beth A Overmoyer and Charles L. Shapiro and John Jae Won Park and Gail T. Colbern and Eric P. Winer and Alberto Gabizon},
  journal={Seminars in oncology},
  year={2004},
  volume={31 6 Suppl 13},
  pages={
          106-46
        }
}
For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active as any--and more active than most--drugs used to treat breast cancer. Their inclusion in combinations to treat early and advanced disease prolongs survival. However, they cause… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Lipid-Based Nanoparticles in Cancer Diagnosis and Therapy

  • Journal of drug delivery
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND